STRUCTURE THERAPEUTICS INC (GPCR) Stock Price, Quote, News and Overview
NASDAQ:GPCR - Nasdaq - US86366E1064 - ADR - Currency: USD
GPCR Quote, Performance and Key Statistics
23.1
+1.34 (+6.16%)
The current stock price of GPCR is 23.1 USD. In the past month the price increased by 10.16%. In the past year, price decreased by -40.68%.
GPCR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 62.92 | 775.47B | ||
| JNJ | JOHNSON & JOHNSON | 15.61 | 378.15B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 16.91 | 258.93B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.92 | 218.33B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.12 | 207.41B | ||
| MRK | MERCK & CO. INC. | 10.19 | 195.90B | ||
| PFE | PFIZER INC | 7.09 | 125.00B | ||
| SNY | SANOFI-ADR | 11.42 | 124.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 42.93 | 99.58B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 73.86B | ||
| ZTS | ZOETIS INC | 24.81 | 65.50B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.46 | 46.99B |
Related stock screener links
About GPCR
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 163 full-time employees. The company went IPO on 2023-02-03. The company is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. The company is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The company is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. The company is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). The company is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Company Info
STRUCTURE THERAPEUTICS INC
611 Gateway Blvd Suite 223
South San Francisco CALIFORNIA US
Employees: 136
Company Website: https://structuretx.com/
Investor Relations: https://ir.structuretx.com/
Phone: 16282299277
STRUCTURE THERAPEUTICS INC / GPCR FAQ
What is the stock price of STRUCTURE THERAPEUTICS INC today?
The current stock price of GPCR is 23.1 USD. The price increased by 6.16% in the last trading session.
What is the ticker symbol for STRUCTURE THERAPEUTICS INC stock?
The exchange symbol of STRUCTURE THERAPEUTICS INC is GPCR and it is listed on the Nasdaq exchange.
On which exchange is GPCR stock listed?
GPCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for STRUCTURE THERAPEUTICS INC stock?
19 analysts have analysed GPCR and the average price target is 81.76 USD. This implies a price increase of 253.93% is expected in the next year compared to the current price of 23.1. Check the STRUCTURE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is STRUCTURE THERAPEUTICS INC worth?
STRUCTURE THERAPEUTICS INC (GPCR) has a market capitalization of 1.32B USD. This makes GPCR a Small Cap stock.
How many employees does STRUCTURE THERAPEUTICS INC have?
STRUCTURE THERAPEUTICS INC (GPCR) currently has 136 employees.
What are the support and resistance levels for STRUCTURE THERAPEUTICS INC (GPCR) stock?
STRUCTURE THERAPEUTICS INC (GPCR) has a resistance level at 23.11. Check the full technical report for a detailed analysis of GPCR support and resistance levels.
Should I buy STRUCTURE THERAPEUTICS INC (GPCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GPCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GPCR, evaluating the profitability, health, valuation and growth aspects
- STRUCTURE THERAPEUTICS INC (GPCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- STRUCTURE THERAPEUTICS INC (GPCR) Sales and EPS estimates to see what analysts future expectations are.
- STRUCTURE THERAPEUTICS INC (GPCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- STRUCTURE THERAPEUTICS INC (GPCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- STRUCTURE THERAPEUTICS INC (GPCR) Stock Chart to make your own analysis
- STRUCTURE THERAPEUTICS INC (GPCR) Latest news and press-releases to stay up to date.
Does STRUCTURE THERAPEUTICS INC (GPCR) stock pay dividends?
GPCR does not pay a dividend.
When does STRUCTURE THERAPEUTICS INC (GPCR) report earnings?
STRUCTURE THERAPEUTICS INC (GPCR) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of STRUCTURE THERAPEUTICS INC (GPCR)?
STRUCTURE THERAPEUTICS INC (GPCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
What is the Short Interest ratio of STRUCTURE THERAPEUTICS INC (GPCR) stock?
The outstanding short interest for STRUCTURE THERAPEUTICS INC (GPCR) is 38.81% of its float. Check the ownership tab for more information on the GPCR short interest.
GPCR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GPCR. When comparing the yearly performance of all stocks, GPCR is a bad performer in the overall market: 80.19% of all stocks are doing better.
GPCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GPCR. While GPCR has a great health rating, there are worries on its profitability.
GPCR Financial Highlights
Over the last trailing twelve months GPCR reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS increased by 22.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.56% | ||
| ROE | -14.17% | ||
| Debt/Equity | 0 |
GPCR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to GPCR. The Buy consensus is the average rating of analysts ratings from 19 analysts.